Last reviewed · How we verify
HEXAMINOLEVULINATE — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
HEXAMINOLEVULINATE (HEXAMINOLEVULINATE). Cysview is converted into PpIX and PAPs, which accumulate in neoplastic cells and fluoresce under specific light, aiding cystoscopic detection.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HEXAMINOLEVULINATE TARGET | HEXAMINOLEVULINATE | marketed | 2010-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HEXAMINOLEVULINATE CI watch — RSS
- HEXAMINOLEVULINATE CI watch — Atom
- HEXAMINOLEVULINATE CI watch — JSON
- HEXAMINOLEVULINATE alone — RSS
Cite this brief
Drug Landscape (2026). HEXAMINOLEVULINATE — Competitive Intelligence Brief. https://druglandscape.com/ci/hexaminolevulinate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing